A citation-based method for searching scientific literature

L Belin, M Kamal, C Mauborgne, C Plancher, F Mulot, J-P Delord, A Gonçalves, C Gavoille, C Dubot, N Isambert, M Campone, O Trédan, F Ricci, M Alt, D Loirat, M-P Sablin, X Paoletti, V Servois, C Le Tourneau. Ann Oncol 2017
Times Cited: 46







List of co-cited articles
134 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, Céline Gavoille, Coraline Dubot, Nicolas Isambert, Mario Campone, Olivier Trédan, Marie-Ange Massiani, Cécile Mauborgne,[...]. Lancet Oncol 2015
641
76

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
Christophe Massard, Stefan Michiels, Charles Ferté, Marie-Cécile Le Deley, Ludovic Lacroix, Antoine Hollebecque, Loic Verlingue, Ecaterina Ileana, Silvia Rosellini, Samy Ammari,[...]. Cancer Discov 2017
360
63

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
Daniel D Von Hoff, Joseph J Stephenson, Peter Rosen, David M Loesch, Mitesh J Borad, Stephen Anthony, Gayle Jameson, Susan Brown, Nina Cantafio, Donald A Richards,[...]. J Clin Oncol 2010
432
60

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Jordi Rodon, Jean-Charles Soria, Raanan Berger, Wilson H Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña,[...]. Nat Med 2019
208
28

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller,[...]. Nat Med 2019
257
28

Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.
Christophe Le Tourneau, Maud Kamal, Apostolia-Maria Tsimberidou, Philippe Bedard, Gaëlle Pierron, Céline Callens, Etienne Rouleau, Anne Vincent-Salomon, Nicolas Servant, Marie Alt,[...]. J Natl Cancer Inst 2015
51
19

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.
Apostolia-Maria Tsimberidou, Sijin Wen, David S Hong, Jennifer J Wheler, Gerald S Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Kenneth Aldape,[...]. Clin Cancer Res 2014
148
19

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.
Maria Schwaederle, Melissa Zhao, J Jack Lee, Vladimir Lazar, Brian Leyland-Jones, Richard L Schilsky, John Mendelsohn, Razelle Kurzrock. JAMA Oncol 2016
189
19

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
19

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
Apostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, Jennifer J Wheler, Gerald S Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Rajyalakshmi Luthra,[...]. Clin Cancer Res 2012
375
17

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
17

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.
Maria Schwaederle, Melissa Zhao, J Jack Lee, Alexander M Eggermont, Richard L Schilsky, John Mendelsohn, Vladimir Lazar, Razelle Kurzrock. J Clin Oncol 2015
268
17

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Tracy L Stockley, Amit M Oza, Hal K Berman, Natasha B Leighl, Jennifer J Knox, Frances A Shepherd, Eric X Chen, Monika K Krzyzanowska, Neesha Dhani, Anthony M Joshua,[...]. Genome Med 2016
148
17

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Milan Radovich, Patrick J Kiel, Stacy M Nance, Erin E Niland, Megan E Parsley, Meagan E Ferguson, Guanglong Jiang, Natraj R Ammakkanavar, Lawrence H Einhorn, Liang Cheng,[...]. Oncotarget 2016
57
15

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project.
Andreas Seeber, Guenther Gastl, Christian Ensinger, Gilbert Spizzo, Wolfgang Willenbacher, Florian Kocher, Christoph Leitner, Ella Willenbacher, Arno Amann, Normann Steiner,[...]. Genes Cancer 2016
12
50

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
13

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
O Trédan, Q Wang, D Pissaloux, P Cassier, A de la Fouchardière, J Fayette, F Desseigne, I Ray-Coquard, C de la Fouchardière, D Frappaz,[...]. Ann Oncol 2019
80
13

Precision oncology based on omics data: The NCT Heidelberg experience.
Peter Horak, Barbara Klink, Christoph Heining, Stefan Gröschel, Barbara Hutter, Martina Fröhlich, Sebastian Uhrig, Daniel Hübschmann, Matthias Schlesner, Roland Eils,[...]. Int J Cancer 2017
86
13

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
10

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Jennifer J Wheler, Filip Janku, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel Karp, Gerald S Falchook,[...]. Cancer Res 2016
157
10

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram,[...]. N Engl J Med 2001
10

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.
Marilyn M Li, Michael Datto, Eric J Duncavage, Shashikant Kulkarni, Neal I Lindeman, Somak Roy, Apostolia M Tsimberidou, Cindy L Vnencak-Jones, Daynna J Wolff, Anas Younes,[...]. J Mol Diagn 2017
773
10

A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs.
Derrick S Haslem, S Burke Van Norman, Gail Fulde, Andrew J Knighton, Tom Belnap, Allison M Butler, Sharanya Rhagunath, David Newman, Heather Gilbert, Brian P Tudor,[...]. J Oncol Pract 2017
53
10

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.
Maria Schwaederle, Barbara A Parker, Richard B Schwab, Gregory A Daniels, David E Piccioni, Santosh Kesari, Teresa L Helsten, Lyudmila A Bazhenova, Julio Romero, Paul T Fanta,[...]. Mol Cancer Ther 2016
110
10


Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).
Fabrice André, Thomas Bachelot, Frederic Commo, Mario Campone, Monica Arnedos, Véronique Dieras, Magali Lacroix-Triki, Ludovic Lacroix, Pascale Cohen, David Gentien,[...]. Lancet Oncol 2014
273
10

OncoKB: A Precision Oncology Knowledge Base.
Debyani Chakravarty, Jianjiong Gao, Sarah M Phillips, Ritika Kundra, Hongxin Zhang, Jiaojiao Wang, Julia E Rudolph, Rona Yaeger, Tara Soumerai, Moriah H Nissan,[...]. JCO Precis Oncol 2017
960
10

Molecular Tumor Boards: current practice and future needs.
D L van der Velden, C M L van Herpen, H W M van Laarhoven, E F Smit, H J M Groen, S M Willems, P M Nederlof, M H G Langenberg, E Cuppen, S Sleijfer,[...]. Ann Oncol 2017
66
10

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
John D Hainsworth, Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R Spigel, Christopher Sweeney, Howard Burris, Ron Bose, Bongin Yoo, Alisha Stein,[...]. J Clin Oncol 2018
251
10

The spectrum of clinical trials aiming at personalizing medicine.
Christophe Le Tourneau, Maud Kamal, Marie Alt, Loic Verlingue, Vincent Servois, Marie-Paule Sablin, Nicolas Servant, Xavier Paoletti. Chin Clin Oncol 2014
13
30

Emerging landscape of oncogenic signatures across human cancers.
Giovanni Ciriello, Martin L Miller, Bülent Arman Aksoy, Yasin Senbabaoglu, Nikolaus Schultz, Chris Sander. Nat Genet 2013
840
8

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.
C Le Tourneau, X Paoletti, N Servant, I Bièche, D Gentien, T Rio Frio, A Vincent-Salomon, V Servois, J Romejon, O Mariani,[...]. Br J Cancer 2014
51
8

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
8

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
8

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
8

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
B J Druker, M Talpaz, D J Resta, B Peng, E Buchdunger, J M Ford, N B Lydon, H Kantarjian, R Capdeville, S Ohno-Jones,[...]. N Engl J Med 2001
8

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.
Vladimir Lazar, Eitan Rubin, Stephane Depil, Yudi Pawitan, Jean-François Martini, Jesus Gomez-Navarro, Antoine Yver, Zhengyin Kan, Jonathan R Dry, Jeanne Kehren,[...]. Oncotarget 2015
20
20

Targeted therapies: What have we learned from SHIVA?
Christophe Le Tourneau, Razelle Kurzrock. Nat Rev Clin Oncol 2016
17
23

Implementing Genome-Driven Oncology.
David M Hyman, Barry S Taylor, José Baselga. Cell 2017
272
8

Precision medicine: lessons learned from the SHIVA trial.
Apostolia M Tsimberidou, Razelle Kurzrock. Lancet Oncol 2015
40
10


Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
8

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.
Denis L Jardim, Maria Schwaederle, Caimiao Wei, J Jack Lee, David S Hong, Alexander M Eggermont, Richard L Schilsky, John Mendelsohn, Vladimir Lazar, Razelle Kurzrock. J Natl Cancer Inst 2015
122
8

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
8

The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.
L R Yates, J Seoane, C Le Tourneau, L L Siu, R Marais, S Michiels, J C Soria, P Campbell, N Normanno, A Scarpa,[...]. Ann Oncol 2018
48
8

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?
Sarah Watson, Jessica Menis, Capucine Baldini, Patricia Martin-Romano, Jean-Marie Michot, Antoine Hollebecque, Jean-Pierre Armand, Christophe Massard, Jean-Charles Soria, Sophie Postel-Vinay,[...]. Br J Cancer 2018
7
57

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire. Science 1987
6

Rare cancers are not so rare: the rare cancer burden in Europe.
Gemma Gatta, Jan Maarten van der Zwan, Paolo G Casali, Sabine Siesling, Angelo Paolo Dei Tos, Ian Kunkler, Renée Otter, Lisa Licitra, Sandra Mallone, Andrea Tavilla,[...]. Eur J Cancer 2011
385
6

Mutational landscape and significance across 12 major cancer types.
Cyriac Kandoth, Michael D McLellan, Fabio Vandin, Kai Ye, Beifang Niu, Charles Lu, Mingchao Xie, Qunyuan Zhang, Joshua F McMichael, Matthew A Wyczalkowski,[...]. Nature 2013
6

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall,[...]. N Engl J Med 2013
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.